Nonclinical evaluation for anticancer pharmaceuticals
- Step 4 -
Guidance Development

- **S9 Guidance Timeline**
  - Business plan proposed by US PhRMA
  - Endorsed by ICH Steering Committee May 2007
    - Driver for guidance:
      - separate regional oncology guidances were being developed
      - in the absence of an oncology guidance, recommendations outlined in ICH M3 and S6 were being requested
  - First meeting Yokohama Japan Oct 2007
    - Japan, EU, and US discussed current and proposed approaches to anticancer drug and biological development

- **Milestones**
  - Additional meetings Portland OR (June 2008); Brussels (Nov 2008); Yokohama (June 2009)
  - Planned release:
    - Step 2: October 2008
    - Step 4: Oct 2009
Guidance Development

ICH:
- ICH S9 Step 2 guidance document is available from the ICH website (ICH.org).

Status
- Public comment period closed earlier this year
- Approximately 215 comments received
- Comments discussed in Yokohama in June 2009
  - EWG revised the Step 2 document
- EWG completed discussions to reach Step 4
- The document provides clarity in recommendations to facilitate regional implementation
Prior Accomplishments

- Approaches to setting a safe start dose for clinical trials
- Study design to support initial clinical development
- Duration of repeated dose toxicity testing limited to 3 months
  - Available prior to phase 3
- Reproduction toxicology requirements to only embryo-fetal toxicology assessment
  - Not essential for pharmaceuticals that target rapidly dividing cells
Update on Accomplishments

- Agreement on language of scope
- Agreed on flexible approach to safety evaluation of metabolites and impurities relative to available regional and ICH guidance
- Agreement on the scientific discussion on need for recovery groups
- Agreement on photosafety testing appropriate to the patient population
- Agreement on studies to support pharmaceutical combinations
- Step 4 reached ahead of the business plan timeframe
Accomplishments

- In all discussions the 3 R’s were kept in focus to ensure the goals in the concept paper are followed
- Identified areas of other guidance that can be used to reduce possible future maintenance, e.g. use of S6 for biopharmaceuticals testing
- Accepted by FDA legal review without substantial revision
Members of ICH S9 EWG

- EU
  - Klaus Olejniczak - BfArM – TL
  - Mikael Andersson – MPA – DTL
  - Hermann Schweinfurth - Bayer Schering Pharma - TL
  - Marco Brughera - Nerviano Pharmaceuticals - DTL

- Japan
  - Hiroshi Onodera - MHLW/PMDA - TL
  - Osamu Fueki - MHLW/PMDA - DTL
  - Dai Nakae - MHLW - Expert
  - Shuichi Kai – Bristol-Myers – TL
  - Chihiro Nishimura – Nippon Kayaku - DTL
  - Atsushi Sanbuissho – Daiichi Sankyo – Expert (To July 2009)
  - Takahiro Nakazawa – Eli Lilly – Expert (To July 2008)
Members of ICH S9 EWG

- **USA**
  - John Leighton - US FDA CDER–TL/Rapporteur
  - Mercedes Serabian - US FDA CBER - DTL
  - Ann Pilaro - US FDA CDER - Expert
  - Daniel Lapadula - Novartis TL
  - Vijayapal Reddy - Eli Lilly – DTL

- **Observers**
  - James Green - Biogen – BIO
  - Helen Mao - Health Canada (To July 2009)
  - Tatiana Lejen - Health Canada (July 2009-present)
  - Beat Schmid – Swissmedic

- **Others**
  - David Jacobson-Kram and Joseph DeGeorge

- And many thanks to colleagues in our organizations that contributed to the development of the guidance